Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Xencor, Inc.
Incyte Corporation
Genentech, Inc.
TransThera Sciences (Nanjing), Inc.
Stanford University
AstraZeneca
Xencor, Inc.
TransThera Sciences (Nanjing), Inc.
Eli Lilly and Company
Corvus Pharmaceuticals, Inc.
Tempest Therapeutics
Xencor, Inc.
Evelo Biosciences, Inc.
Nektar Therapeutics
Novartis
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
Incyte Corporation
MacroGenics
Incyte Corporation
Gilead Sciences
AstraZeneca
Incyte Corporation
Stanford University
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)